Read the data brief here.
Additionally, Dan O'Day, the CEO of Gilead, promised on CNBC and in an open letter that Remdesivir would have a lower 'government price' in the U.S. for a five-day course. However, the discount will only apply to a select group of smaller government programs, excluding Medicare and Medicaid. Dr. Bach proposes two options if Gilead wishes to discount Remdesivir to the full array of government programs.
Read the data brief here.